Trial Profile
Pharmacokinetics of Apixaban in Nephrotic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Nephrotic syndrome; Proteinuria
- Focus Pharmacokinetics
- 23 Jul 2019 Status changed from recruiting to completed.
- 04 May 2018 Planned End Date changed from 30 Sep 2018 to 1 Apr 2019.
- 04 May 2018 Planned primary completion date changed from 30 Apr 2018 to 1 Apr 2019.